⌘+K

Company description

EQL was founded in 2006 by Christer Fåhraeus and Karin Wehlin with the goal of capitalising on inefficient drug markets characterised by slow price erosion following generic entries. In 2008, the company launched its first product in Sweden – a generic version of the antidepressant drug venlafaxine (Effexor). Shortly thereafter, it shifted its strategy to focus on niche generic markets. Over the subsequent years, EQL introduced its initial niche generics in Finland, Denmark and Norway, and more recently expanded its presence into continental Europe.

Key industry drivers

  • Growing need for niche providers of off-patent drugs.

  • Local differences and low competition for niche products.

  • Continuous stream of patent expirations.

Industry outlook

  • We expect the market for small-volume generics to grow and consolidate as larger pharma companies focus on high-value products, leaving gaps that smaller names such as EQL can fill.

  • Key peers

    Key peers are listed companies with high exposure to the generics market.

    Shareholders

    Name

    Capital

    Votes

    Cadila Pharmaceuticals Ltd

    30.0 %

    30.0 %

    Christer Fåhraeus

    23.7 %

    23.7 %

    Consensus Asset Management

    3.3 %

    3.3 %

    SEB Funds

    3.2 %

    3.2 %

    Avanza Pension

    2.8 %

    2.8 %

    Nordnet Pensionsförsäkring

    2.7 %

    2.7 %

    About DNB Carnegie Access

    DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

    Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

    Private Banking

    Tailored wealth management. Your financial future, personalized.

    Montrose

    A digital investment platform designed for passionate investors.

    DNB Carnegie

    Leading Nordic investment bank and wealth management.

    © Copyright DNB Carnegie Investment Bank AB